[1] Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care [J]. Nat Rev Rheumatol, 2020, 16(12):702-714. [2] Sánchez-Oro R, Alonso-Muñoz EM, Martí Romero L. Review of IgG4-related disease [J]. Gastroenterol Hepatol, 2019, 42(10):638-647. [3] Lanzillotta M, Fernàndez-Codina A, Culver E, et al. Emerging therapy options for IgG4-related disease [J]. Expert Rev Clin Immunol, 2021, 17(5):471-483. [4] Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease [J]. Ann Rheum Dis, 2020, 79(1):77-87. [5] Tang J, Cai S, Ye C, et al. Biomarkers in IgG4-related disease: A systematic review [J]. Semin Arthritis Rheum, 2020, 50(2):354-359. [6] Maehara T, Moriyama M, Nakamura S. Pathogenesis of IgG4-related disease: a critical review [J]. Odontology, 2019, 107(2):127-132. [7] Umehara H, Okazaki K, Kawa S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD [J]. Mod Rheumatol, 2021, 31(3):529-533. [8] 王子乔,刘燕鹰,张霞,等.17例误诊为IgG4相关疾病患者的临床特点及误诊原因分析[J].北京大学学报(医学版),2019,51(6):1025-1031. [9] 张文,董凌莉,朱剑,等.IgG-4相关性疾病诊治中国专家共识[J].中华内科杂志,2021,60(03):192-206. |